Paper42266751
Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism.
Zhou Y and 6 others. Am J Cancer Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism. Papers, record 42266751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42266751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Schisandrin A suppresses hepatocellular carcinoma and sensitizes to sorafenib via modulating retinol metabolism.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39838407 | Tailoring traditional Chinese medicine in cancer therapy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/39838407 | PubMed |
| 2 | 34256124 | Treatment for liver cancer: From sorafenib to natural products. | Eur J Med Chem | 2021 | https://conductscience.org/library/papers/34256124 | PubMed |
| 3 | 34643254 | Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy. | Int J Mol Med | 2021 | https://conductscience.org/library/papers/34643254 | PubMed |
| 4 | 32889778 | Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. | Cancer Sci | 2020 | https://conductscience.org/library/papers/32889778 | PubMed |
| 5 | 40490812 | Natural anti-cancer products: insights from herbal medicine. | Chin Med | 2025 | https://conductscience.org/library/papers/40490812 | PubMed |
| 6 | 39599215 | Magnetic Molecularly Imprinted Polymer Combined with Solid-Phase Extraction for Purification of Schisandra chinensis Lignans. | Polymers (Basel) | 2024 | https://conductscience.org/library/papers/39599215 | PubMed |
| 7 | 37910285 | Schisandrin A Alleviates Spatial Learning and Memory Impairment in Diabetic Rats by Inhibiting Inflammatory Response and Through Modulation of the PI3K/AKT Pathway. | Mol Neurobiol | 2024 | https://conductscience.org/library/papers/37910285 | PubMed |
| 8 | 40424981 | Icaritin induces paraptosis in hepatocellular carcinoma cells by targeting BHLHE40 via endoplasmic reticulum stress and mitochondrial dysfunction. | Phytomedicine | 2025 | https://conductscience.org/library/papers/40424981 | PubMed |
| 9 | 38382281 | Schisandrin A alleviates renal fibrosis by inhibiting PKCβ and oxidative stress. | Phytomedicine | 2024 | https://conductscience.org/library/papers/38382281 | PubMed |
| 10 | 39354529 | Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39354529 | PubMed |
| 11 | 40513323 | Efficacy and safety of Chinese medicine in treating risk window of AECOPD: A multicenter randomized controlled trial. | Phytomedicine | 2025 | https://conductscience.org/library/papers/40513323 | PubMed |
| 12 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 13 | 39949800 | Material basis revelation of anti-hepatoma effect of Huachansu (Cinobufacini) through down-regulation of thymidylate synthase. | Chin Herb Med | 2025 | https://conductscience.org/library/papers/39949800 | PubMed |
| 14 | 32110802 | Schizandrin A exhibits potent anticancer activity in colorectal cancer cells by inhibiting heat shock factor 1. | Biosci Rep | 2020 | https://conductscience.org/library/papers/32110802 | PubMed |
| 15 | 36604718 | Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36604718 | PubMed |
| 16 | 36175804 | The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. | Med Oncol | 2022 | https://conductscience.org/library/papers/36175804 | PubMed |
| 17 | 40392748 | Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/40392748 | PubMed |
| 18 | 38552434 | Lignan contents of Schisandra chinensis (Turcz.) Baill. from different origins-A new model for evaluating the content of prominent components of Chinese herbs. | Phytomedicine | 2024 | https://conductscience.org/library/papers/38552434 | PubMed |
| 19 | 40475000 | Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study). | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40475000 | PubMed |
| 20 | 35345394 | The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma. | Onco Targets Ther | 2022 | https://conductscience.org/library/papers/35345394 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42266751
GET https://conductscience.org/api/papers/v1/42266751/references?page=2